3SBio Inc. (HKG:1530)

Market Cap	31.54B
Revenue (ttm)	9.69B
Net Income (ttm)	2.22B
Shares Out	2.36B
EPS (ttm)	0.90
PE Ratio	14.79
Forward PE	12.20
Dividend	0.25 (1.95%)
Ex-Dividend Date	Jul 21, 2025

Volume	50,198,589
Average Volume	61,702,335
Open	12.96
Previous Close	12.80
Day's Range	12.72 - 13.60
52-Week Range	5.47 - 13.84
Beta	0.65
RSI	62.36
Earnings Date	May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY